Targeting a specific immune cell could protect against antibiotic-induced breast cancer progression
15th September 2021
Leading scientists have identified a possible link between antibiotic use and the speed of breast cancer growth in mice, and identified a type of immune cell that could be targeted to reverse it.
In a new study funded by Breast Cancer Now, researchers from the Quadram Institute and the University of East Anglia found that treating mice with broad-spectrum antibiotics increased the rate at which breast cancer tumours grew in them. They also observed an increase in the size of secondary tumours that grew in other organs when the cancer spread.
Led by Dr Stephen Robinson, Group Leader at the Quadram Institute and Research Leader at UEA, the team used a cocktail of five antibiotics, and broad-spectrum antibiotic cefalexin on its own, to investigate how disrupting a healthy balance of bacteria in the gut affected breast cancer growth in mice.
The researchers discovered that the use of antibiotics led to the loss of a beneficial bacterial species, which in turn sped up tumour growth. Through further investigation, the team also found that a type of immune cell, known as mast cells, were found in larger numbers in breast cancer tumours in mice treated with antibiotics. Blocking the function of these cells also reversed the effect of antibiotics and reduced the aggressive growth of the tumours.
It is hoped that these results could lead to a refinement of antibiotic use in people affected by breast cancer, and the development of new ways to counteract the negative effects that certain antibiotics could have on breast cancer.
This is important as while chemotherapy is a cornerstone of breast cancer treatment it reduces the number of white blood cells in the blood, making people more susceptible to infection. Antibiotics are therefore often prescribed to breast cancer patients to control any infections that arise during chemotherapy treatment.
Breast cancer is the most common cancer in women in the UK, with around 55,000 women and 370 men being diagnosed in the UK each year. Secondary (or metastatic) breast cancer occurs when primary breast cancer cells spread from the breast, through the lymphatic or blood system to other parts of the body. It is not currently known how many people have secondary breast cancer, but it is estimated that 35,000 people in the UK are living with this devastating incurable disease, and the fear and uncertainty of when it will cut their lives short .
In this new research, published in iScience, Dr Stephen Robinson and PhD student Alastair McKee discovered that breast tumours grew faster in mice that were given antibiotics, compared to mice that didn’t receive antibiotic treatment. This effect was observed in mice models of the disease representing several different types of breast cancer.
The team further investigated the changes that treatment with antibiotics leads to and noticed that mice that were treated with antibiotics had an increased number of mast cells in breast tumours.
The researchers found that cromolyn, a substance that stops mast cells from working and is used to treat some other health conditions, reduced tumour growth in the antibiotic-treated mice, but not in the control group. This provides evidence that mast cells could be involved in the faster growth of breast cancer that arises from antibiotic use.
Researchers will now investigate further to understand where the increase of mast cells comes from, and why the disruption of the gut bacteria causes an increase in mast calls.
In the future, patients who need to take broad-spectrum antibiotic treatment could also be given treatments that block this negative effect of antibiotics to stop the growth of breast cancer whilst also ensuring that people are protected from chemotherapy-induced infections. It could also be possible to identify which antibiotics have the least impact on breast cancer progression.
Dr Stephen Robinson, Group Leader at the Quadram Institute and Research Leader at UEA, said: “With the rise in bacteria resistance to antibiotics we have known for many years that we need to be very careful about clinical antibiotic use. This research further demonstrates the important role a healthy gut microbiota plays in regulating the body’s response to disease and that antibiotics play a significant role in unbalancing a healthy gut microbiome.
“Our research has shown that losing “good” bacteria in the gut, as the result of antibiotic use, can lead to an increased rate of breast cancer growth. We believe there is a complex immune element to this mechanism involving mast cells, a type of cell whose role in many cancers is not yet fully understood. Therefore, future studies will focus on understanding the possible role of these cells as well as looking into the effects of introducing probiotics into the experimental models we use.”
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said: “One woman is diagnosed with breast cancer every 10 minutes in the UK and we urgently need to find new ways to treat patients and prevent more people dying from this devastating disease. This cutting-edge research gives us vital new knowledge into how breast cancer tumours can grow.
“Whilst the link between antibiotics and breast cancer growth may sound alarming, we want to remind everyone affected by breast cancer that this is early stage research that has currently only been tested in mice. Much more work is needed to understand the complex relationship between gut bacteria and breast cancer. However, this research does provide crucial insight and we must now further investigate the effect of antibiotics in breast cancer treatment so that we can find the best way to stop tumours from growing. Excitingly, this research has already highlighted that by targeting mast cells, we could potentially halt antibiotic-induced breast cancer growth.
“We’re proud to have funded this research, especially at a time when the COVID-19 pandemic has profoundly impacted our world-class research – we’ve been less able to fund new research that could transform the lives of people affected by breast cancer. This is why your support is more critical now than ever before in helping us to continue to bring hope for the future through our research. For more information and to donate visit www.breastcancernow.org/donate.”
Breast Cancer Now is grateful to Asda Tickled Pink for their generous financial support of Dr Robinson’s project.
For more information or to arrange an interview, please contact the Breast Cancer Now press office at firstname.lastname@example.org or on 07436 107914.
Notes to Editors
About Breast Cancer Now:
• Breast Cancer Now is the UK’s first comprehensive breast cancer charity, combining world-class research and life-changing care.
• Breast Cancer Now’s ambition is that, by 2050, everyone who develops breast cancer will live and be supported to live well.
• Breast Cancer Now, the research and care charity, launched in October 2019, created by the merger of specialist support and information charity Breast Cancer Care and leading research charity Breast Cancer Now.
• Visit breastcancernow.org or follow us on Twitter or on Facebook.
• Anyone looking for support or information can call Breast Cancer Now’s free Helpline on 0808 800 6000.